Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/99ADE2AC.svg?ark=w1%2F20260526%2F99ADE2AC&value=id)](https://nobleid.org/work/w1/20260526/99ADE2AC)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors